Nuclear IRF-1 expression as a mechanism to assess “Capability” to express PD-L1 and response to PD-1 therapy in metastatic melanoma

Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy

(2017) Jarushka Naidoo et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

(2017) Fred R. Hirsch et al.   Journal of Thoracic Oncology

Deubiquitination and Stabilization of PD-L1 by CSN5

(2016) Seung-Oe Lim et al.   CANCER CELL

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

(2016) Jianjun Gao et al.   CELL

PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis

(2016) Sara Gandini et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

(2016) Antoni Ribas et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab

(2016) Jeroen de Filette et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Critical renal adverse event induced by nivolumab therapy in a stage IV melanoma patient

(2016) Aya Tanaka et al.   JOURNAL OF DERMATOLOGY

Immune-checkpoint blockade — durable cancer control

(2016) Elizabeth I. Buchbinder et al.   Nature Reviews Clinical Oncology

Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells

(2016) B. Homet Moreno et al.   Cancer Immunology Research

Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis

(2016) Omar Abdel-Rahman et al.   Therapeutic Advances in Respiratory Disease

Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer

(2016) Joseph McLaughlin et al.   JAMA Oncology

IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer

(2015) K Abiko et al.   BRITISH JOURNAL OF CANCER

Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites

(2015) H. M. Kluger et al.   CLINICAL CANCER RESEARCH

Anti–PD-1 and Anti–PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes

(2015) Mahnaz Mellati et al.   DIABETES CARE

Pseudoprogression and Immune-Related Response in Solid Tumors

(2015) Victoria L. Chiou et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

(2014) Caroline Robert et al.   LANCET

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer

(2014) H. Wimberly et al.   Cancer Immunology Research

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

An immunologic portrait of cancer

(2011) Maria Ascierto et al.   Journal of Translational Medicine

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER